Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw an uptick in trading volume on Thursday . 3,479,674 shares changed hands during mid-day trading, an increase of 17% from the previous session’s volume of 2,965,967 shares.The stock last traded at $10.4050 and had previously closed at $9.36.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Analyst support provided a counterpoint to the negative legal headlines: Oppenheimer raised Capricor to Outperform, and another report attributed a sharp move in the shares to an analyst upgrade. These actions suggest some analysts continue to see potential value in deramiocel and Capricor’s pipeline. Capricor Therapeutics Raised to Outperform at Oppenheimer
• Neutral Sentiment: The FDA extended its review period for Capricor’s Biologics License Application for deramiocel. The extension does not by itself indicate approval or rejection, but it delays regulatory clarity and leaves investors focused on the timing and outcome of the review. Hagens Berman FDA Review Extension Alert
• Negative Sentiment: Multiple law firms publicized an existing securities-fraud class action and the September 28, 2026 deadline for investors to seek lead-plaintiff status. The complaints allege that Capricor and certain executives made misleading statements or omissions concerning the HOPE-3 trial’s prespecified statistical analysis plan and FDA compliance. The repeated alerts increase reputational, legal-cost, disclosure and potential-liability concerns, although the allegations have not been proven. Kaplan Fox Capricor Securities Fraud Class Action Notice
• Negative Sentiment: Recent quarterly results also add pressure: Capricor reported a larger-than-expected loss of $0.70 per share versus the $0.59 consensus estimate, and a reported lack of analyst Q&A during the earnings call may reinforce concerns about transparency and near-term execution.

Analyst Ratings Changes

CAPR has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Roth Capital downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research report on Monday, July 27th. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research note on Tuesday, July 28th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. Finally, Piper Sandler cut shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price target on the stock. in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Hold” and a consensus target price of $29.15.

Capricor Therapeutics Stock Performance

The stock has a 50 day moving average price of $14.46 and a two-hundred day moving average price of $24.30. The company has a market capitalization of $557.56 million, a PE ratio of -3.91 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current year.

Insiders Place Their Bets

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 25,000 shares of company stock worth $759,158 over the last 90 days. 9.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Montanova Capital LLC raised its holdings in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $49,062,000. Finally, California State Teachers Retirement System increased its position in Capricor Therapeutics by 2,261.8% during the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock worth $36,806,000 after buying an additional 1,463,762 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.